NexImmune, Inc.
NEXIDelisted Sep 6, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001538210
NexImmune, Inc. was delisted on Sep 6, 2024; its insiders filed their last Form 4 on Jun 13, 2024; 13 institutions reported holding it in 13F filings for Q2 2024, worth $408.6K in total; no superinvestor held it.
13F holders, Q3 2024
Institutional positions in NexImmune, Inc. as of Sep 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
NEXI is no longer listed, and 13F filings after Q2 2024 list far fewer holders. See Q2 2024
- Institutional holders
- 1
- −12 vs. Q2 2024
- Shares held
- 10.8K
- −137.3K (−92.7%) vs. Q2 2024
- Total value
- $2.70K
- −$405.9K (−99.3%) vs. Q2 2024
- New holders
- 0
- 0 more added
- Sold out
- 12
- 0 more reduced
Compare with Q2 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting NEXI on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 1 | $2.70K |
| Q2 2024 | 13 | $408.6K |
| Q1 2024 | 12 | $858.3K |
| Q4 2023 | 11 | $229.4K |
| Q3 2023 | 31 | $921.4K |
| Q2 2023 | 32 | $1.26M |
| Q1 2023 | 31 | $2.20M |
| Q4 2022 | 29 | $1.45M |
| Q3 2022 | 39 | $4.34M |
| Q2 2022 | 46 | $13.4M |
| Q1 2022 | 52 | $40.1M |
| Q4 2021 | 46 | $47.1M |
| Q3 2021 | 47 | $160.3M |
| Q2 2021 | 42 | $119.0M |
| Q1 2021 | 46 | $184.9M |
Institutions, Q3 2024
Shares, value and share of portfolio for each institution holding NexImmune, Inc.; share changes are against Q2 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Raymond James & Associates | 10,804 | $2.70K | 0.00% | 00.0% | Unchanged |
| Sabby Management, LLC | 0 | $0 | 0.00% | −49,904−100.0% | Sold out |
| Slate Path Capital LP | 0 | $0 | 0.00% | −36,999−100.0% | Sold out |
| EPIQ Capital Group, LLC | 0 | $0 | 0.00% | −15,624−100.0% | Sold out |
| The PNC Financial Services Group, Inc. | 0 | $0 | 0.00% | −12,640−100.0% | Sold out |
| Vanguard Group Inc | 0 | $0 | 0.00% | −12,010−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −4,000−100.0% | Sold out |
| Comerica Bank | 0 | $0 | 0.00% | −3,256−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −2,121−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −638−100.0% | Sold out |
| BNP Paribas Arbitrage, SA | 0 | $0 | 0.00% | −41−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −7−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −102−100.0% | Sold out |